7T MRI and visual perception markers for severe mood and psychotic disorders
Official title: Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07479758 · Data updated 2026-11-12
This project tests whether 7‑tesla MRI scans combined with visual perception tests can identify brain markers linked to diagnosis and treatment outcomes in adults with major depressive disorder, bipolar disorder, or schizophrenia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 320 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | March 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | April 28, 2026 |
| Trial ID | NCT07479758 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–45 with a DSM‑5 diagnosis of major depressive disorder, schizophrenia, or bipolar disorder who can provide informed consent, have no severe medical or neurological illness, and can safely undergo MRI are ideal candidates.
✕Probably not a fit
Patients who cannot have an MRI (metal implants, pacemaker, severe claustrophobia), are pregnant, have major medical or neurological comorbidities, or fall outside the 18–45 age range are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project uses ultra‑high‑field (7T) multimodal MRI, including structural, functional, and magnetic resonance spectroscopy, together with standardized visual perception tasks to measure brain changes in people with severe mental disorders. Participants include adults with DSM‑5 diagnoses of major depressive disorder, schizophrenia, or bipolar disorder, plus healthy controls. Imaging and behavioral measures are collected before and after clinical treatment to look for metabolic and connectivity changes that track symptoms and outcomes. The goal is to develop a biomarker system that complements symptom-based diagnosis and helps predict treatment response.
Why it matters
Potential benefit: If successful, the work could provide objective brain and visual-processing markers to improve diagnostic precision and help predict which patients will respond to treatment.
How similar studies have gone: Prior work using high‑field MRI and visual‑perception measures has produced promising but inconsistent biomarker signals, and multimodal 7T approaches remain relatively new and not yet clinically validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants aged 18 to 45 years old at the time of enrollment * Male or female participants * For patients: A diagnosis of major depressive disorder (MDD), schizophrenia (SZ), or bipolar disorder (BD) based on DSM-5 criteria * For healthy controls: No history of any mental health disorders * No current severe medical illnesses or history of brain injury such as encephalitis * Ability to provide written informed consent by the participant or their guardian Exclusion Criteria: * History of head injury or brain diseases such as epilepsy * Presence of severe physical illnesses such as tumors or thyroid problems * Presence of metal implants in the body like pacemakers or brain devices * Fear of enclosed spaces (claustrophobia) or inability to undergo an MRI scan * Current pregnancy
Where it's running
-
Second Affiliated Hospital, School of Medicine, Zhejiang
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Zheng Lin
- Email: Linzzr@126.com
- Phone: 86-13757118261
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of comorbidity on people with severe mental illness
This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.
-
Venous Tourniquet with Low-Dose Sugammadex vs Arterial Tourniquet for Seizure Monitoring During ECT
40 patients undergoing ECT will have a venous tourniquet on one arm and an arterial tourniquet on the other to see which method better reveals motor seizures.
-
Emotional Eating, Sleep Quality, Mental State, and Metabolic Syndrome in Psychiatric Patients
This study tests how mood, sleep, and emotional eating relate to metabolic syndrome in people with schizophrenia or bipolar disorder.
-
À deux, c'est mieux — group program to improve romantic relationships for young adults with severe mental illness
This program will try a 12-week, small-group course to help single adults with severe mental illness build skills for dating, communication, and closer social relationships.
-
Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor
This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.
-
Enhancing Veteran-Clinician Collaboration in VA Care for Serious Mental Illness
This study tests a 10-session group program to help Veterans with serious mental illness collaborate better with their clinicians and care teams.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.